AUD/HUF Spot/
| 5/24/2024 9:59:59 PM | Chg. -1.2415 | Volume | Bid9:59:59 PM | Ask9:59:59 PM | High | Low |
|---|---|---|---|---|---|---|
| 234.6390HUF | -0.53% | 50,010 Turnover: 11.77 mill. |
234.5380Bid Size: 1 | 234.7400Ask Size: 1 | 236.1161 | 234.4407 |
GlobeNewswire
4/10
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and Hi...
GlobeNewswire
2/13
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trade...
GlobeNewswire
10/25/2023
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorde...
GlobeNewswire
2/22/2022
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Diso...
GlobeNewswire
12/9/2021
BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcoho...
GlobeNewswire
10/26/2021
Soberlink and the National Council of Juvenile and Family Court Judges Create Judge's Bench Card to ...
Newsfile Corp
10/25/2021
International Lithium Corp. Expands Raleigh Lake Lithium and Rubidium project in Ontario, Canada and...
GlobeNewswire
9/30/2021
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Tr...
GlobeNewswire
8/10/2021
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid...
GlobeNewswire
6/22/2021
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for G...
GlobeNewswire
6/21/2021
MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disord...
GlobeNewswire
6/7/2021
Adial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of Add...
GlobeNewswire
2/26/2019
Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of...
GlobeNewswire
2/21/2019
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
GlobeNewswire
2/15/2019
Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence a...
GlobeNewswire
2/12/2019
Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Adva...
GlobeNewswire
1/17/2019
Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Boar...
GlobeNewswire
12/10/2018
Adial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at th...
GlobeNewswire
9/18/2018
Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europ...
GlobeNewswire
9/12/2018
Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results
